Skip to main content
INSMED Inc logo

INSMED Inc — Investor Relations & Filings

Ticker · INSM ISIN · US4576693075 LEI · 529900Q55QAG41CCAC11 US Manufacturing
Open in API
Filings indexed 1,323 across all filing types
Latest filing 2018-01-26 Capital/Financing Update
Country US United States of America
Listing US INSM

About INSMED Inc

https://insmed.com/

Insmed Incorporated is a global biopharmaceutical company dedicated to developing and commercializing therapies for patients with serious and rare diseases. The company's primary focus is on addressing areas of high unmet medical need. Its marketed product, Arikayce (liposomal amikacin for inhalation), is a treatment for Mycobacterium avium complex (MAC) lung disease. Insmed leverages proprietary technologies, such as its advanced liposomal pulmonary delivery system, to create novel treatments. The company maintains a diverse pipeline of investigational medicines and is actively advancing potential new therapies through various stages of clinical trials.

Recent filings

Filing Released Lang Actions
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated January 22, 2018, reporting an underwritten public offering of convertible senior notes by Insmed Incorporated. It details the underwriting agreement, the offering terms, and related legal opinions. The content focuses on a financing event and capital raising activity. There is no indication of financial statements, earnings data, management discussion, or other report types. The document is not a report publication announcement but a current report on a material event. Therefore, it fits the category of Capital/Financing Update (CAP).
2018-01-26 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a detailed prospectus supplement and accompanying prospectus related to a $400 million offering of 1.75% Convertible Senior Notes due 2025 by Insmed Incorporated. It includes detailed terms of the notes, underwriting information, risk factors, use of proceeds, and legal matters. The document is filed pursuant to Rule 424(b)(5) under the Securities Act of 1933, which is a common filing for securities offerings. This type of document is a capital/financing update as it provides information about a new debt issuance and related financing terms. It is not an annual or interim report, audit report, earnings release, or any other category. The length and content confirm it is the actual offering document, not just an announcement or a brief summary. Therefore, the correct classification is Capital/Financing Update (CAP).
2018-01-24 English
FWP
Capital/Financing Update Classification · 100% confidence The document is an Issuer Free Writing Prospectus (FWP) dated January 23, 2018, related to a Convertible Senior Notes Offering by Insmed Incorporated. It contains detailed terms of the convertible notes, including pricing, interest rate, maturity, conversion rates, underwriting details, and use of proceeds. The document is a disclosure related to a financing transaction, specifically a convertible notes offering. It is not a full financial report, earnings release, or management discussion. It is not a proxy, voting result, or governance document. The document is a detailed update on a capital raising activity, consistent with a Capital/Financing Update filing. The length is about 10,995 characters, which is substantive and not a mere announcement or report publication notice. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2018-01-24 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a preliminary prospectus supplement related to a $300 million offering of convertible senior notes due 2025. It includes detailed terms of the offering, interest rates, conversion rights, redemption provisions, and underwriting information. The document references SEC registration numbers and is clearly a filing related to a securities offering. It is not a financial report, earnings release, or management discussion. It is a capital markets document describing a financing transaction. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering terms, not just an announcement or a brief summary, so it is not a Report Publication Announcement or Regulatory Filing. Hence, the classification is CAP with high confidence.
2018-01-22 English
POSASR
Capital/Financing Update Classification · 100% confidence The document is a Post-Effective Amendment No. 1 to a Form S-3 Registration Statement filed with the SEC by Insmed Incorporated. It is a registration statement under the Securities Act of 1933, used for registering securities for sale to the public. The document includes a prospectus describing the terms of securities offerings, including common stock and debt securities, and references to selling securityholders. It is not a financial report, earnings release, or management discussion, but rather a regulatory filing related to capital raising and securities registration. The document is lengthy (15,000 characters) and contains detailed registration and prospectus information, consistent with a Capital/Financing Update filing. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2018-01-22 English
Major Shareholding Notification 2018
Major Shareholding Notification
2018-01-19 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.